文献速递白血病

丙戊酸和维A酸联合地西他滨治疗老年不适合强化疗急性髓系白血病:多中心随机2×2二期试验结果

Valproate and Retinoic Acid in Combination With Decitabine in Elderly Nonfit Patients With Acute Myeloid Leukemia: Results of a Multicenter, Randomized, 2 × 2, Phase II Trial.
PubMed 文献 · J Clin Oncol · 2019-12-03

结果显示加用ATRA提高缓解率(21.9% vs 13.5%)并延长中位总生存(8.2 vs 5.1个月),而丙戊酸无获益,毒性以血液学为主且各组无显著差异。

要点

  • ATRA联合地西他滨提高缓解率并延长生存,且不增加毒性。
  • 丙戊酸联合地西他滨未观察到缓解或生存获益。
  • ATRA的生存获益在各风险组(包括不良细胞遗传学)中均可见。

核心结论

  • 在地西他滨基础上加用ATRA可提高老年不适合强化疗AML患者的缓解率并延长生存,且不增加毒性。
  • 加用丙戊酸未观察到缓解率或生存获益。

研究设计与样本

  • 患者接受地西他滨(20 mg/m2静脉注射,第1至5天)单药(n=47)或联合丙戊酸(n=57)、ATRA(n=46)或丙戊酸+ATRA(n=50)。

主要发现

  • 丙戊酸组未观察到生存差异。
  • 毒性以血液学为主,4组间无相关差异。

临床怎么用

  • 对于不适合诱导化疗的老年AML患者,可考虑在地西他滨基础上加用ATRA以改善缓解率和生存。
  • 不推荐在地西他滨基础上常规加用丙戊酸用于该人群。
  • ATRA联合地西他滨未增加毒性,安全性可接受。

局限性

  • 中位年龄76岁,结果可能不适用于更年轻或适合强化疗的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: DNA-hypomethylating agents are studied in combination with other epigenetic drugs, such as histone deacetylase inhibitors or differentiation inducers (eg, retinoids), in myeloid neoplasias. A randomized, phase II trial with a 2 × 2 factorial design was conducted to investigate the effects of the histone deacetylase inhibitor valproate and all-trans retinoic acid (ATRA) in treatment-naive elderly patients with acute myeloid leukemia (AML). PATIENTS AND METHODS: Two hundred patients (median age, 76 years; range, 61-92 years) ineligible for induction chemotherapy received decitabine (20 mg/m2 intravenously, days 1 to 5) alone (n = 47) or in combination with valproate (n = 57), ATRA (n = 46), or valproate + ATRA (n = 50). The primary endpoint was objective response, defined as complete and partial remission, tested at a one-sided significance level of α = .10. Key secondary endpoints were overall survival, event-free survival, and progression-free survival and safety. RESULTS: The addition of ATRA resulted in a higher remission rate (21.9% with ATRA v 13.5% without ATRA; odds ratio, 1.80; 95% CI, 0.86 to 3.79; one-sided P = .06). For valproate, no effect was observed (17.8% with valproate v 17.2% without valproate; odds ratio, 1.06; 95% CI, 0.51 to 2.21; one-sided P = .44). Median overall survival was 8.2 months with ATRA v 5.1 months without ATRA (hazard ratio, 0.65; 95% CI, 0.48 to 0.89; two-sided P = .006). Improved survival was observed across risk groups, including patients with adverse cytogenetics, and was associated with longer response duration. With valproate, no survival difference was observed. Toxicities were predominantly hematologic, without relevant differences between the 4 arms. CONCLUSION: The addition of ATRA to decitabine resulted in a higher remission rate and a clinically meaningful survival extension in these patients with difficult-to-treat disease, without added toxicity.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Lübbert M, Grishina O, Schmoor C, et al. Valproate and Retinoic Acid in Combination With Decitabine in Elderly Nonfit Patients With Acute Myeloid Leukemia: Results of a Multicenter, Randomized, 2 × 2, Phase II Trial. J Clin Oncol. 2019. PMID: 31794324. doi:10.1200/JCO.19.01053

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。